Journal of Hematology Blood Transfusion & Disorders Category: Clinical Type: Mini Review

Chronic Eosinophilic Leukemia: A Mini-Review

Nigel P Murray1*
1 Department of medicine, Hospital de Carabineros de Chile, University Finis Terrae, Providencia, Santiago, Chile

*Corresponding Author(s):
Nigel P Murray
Department Of Medicine, Hospital De Carabineros De Chile, University Finis Terrae, Providencia, Santiago, Chile
Tel:+56 274980507,

Received Date: Nov 12, 2015
Accepted Date: Dec 07, 2015
Published Date: Dec 21, 2015


Eosinophilia has been defined as an absolute eosinophil count of more than 500 eosinophils/mm3 of venous blood [1]. In patients with marked eosinophilia (>1,500 eosinophils/mm3) which persisted for more than six months, the working conference on eosinophil disorders and syndromes proposed in 2011 a new classification [2]. Hypereosinophilia (HE) was classified as familial, underdetermined significance, primary clonal or neoplastic and reactive; when associated with end organ damage it should be classified as Hypereosinophilic Syndrome (HES).

The majority of cases are secondary or reactive, in developing countries most commonly due to infections, especially tissue invasive parasites [3]. Reactive eosinophilia to other tumors, allergy or collagen vascular disease needs to be excluded. The age adjusted incidence for HES is of the order of 0.036 cases/100,000 population, of which Chronic Eosinophilic Leukemia (CEL) comprises a minority of these patients [4].

In 2008, the WHO revised the classification of eosinophilia in myeloid neoplasms, creating a new category; myeloid and lymphoid neoplasms with eosinophilia and abnormalities of Platelet Derived Growth Factor Receptor Alpha (PDGFRA), Platelet Derived Growth Factor Receptor Beta (PDGFRB) or Fibroblast Growth Factor Receptor 1 (FGFR1) [5].

There are two forms of Chronic Eosinophilic Leukemia (CEL) the CEL FIP1L1-PDGFRA rearrangement positive, which is part of the new subcategory of the WHO classification and the CEL-NOS (not otherwise specified) which forms part of the myeloproliferative neoplasms of the WHO classification [6].

CEL is a chronic myeloproliferative disease with a clonal proliferation of eosinophilic precursors. This results in a persistently elevated number of eosinophils in the blood, bone marrow and peripheral tissues [7]. The WHO proposed diagnostic criteria for CEL include: a persistent eosinophilia of ≥1.5 x 109/L in peripheral blood persisting for more than 6 months and increased bone marrow eosinophilia with between 5-19% of myeloblasts in bone marrow samples or >2% in the peripheral blood and clonality of the myeloid cells should be demonstrated [7]. The etiology of CEL is unknown, although two cases associated with occupational or therapeutic radiation exposure have been reported [8]. The available evidence suggests that its incidence is highest in the fourth decade. Differing from other causes of hypereosinophilia where there is no clear gender difference, CEL NOS is more common in males with a ratio of 1.47, whereas CEL FIP1L1-PDGFRA patients are in the majority of cases male and in almost all cases there is clinically palpable splenomegaly [9].

The disease has been characterized by a chronic phase that may progress to a blast crisis. Historical case series reported a high mortality, with a 12 year survival of only 12%, the majority presenting in advanced stages and the dying of cardiac disease caused by the hypereosinophilia [9]. However in the era of molecular defined eosinophilias, improved and earlier diagnosis, the use of targeted therapy and cardiovascular surgery the survival has improved [9].

The neoplastic nature of CEL has been substantiated by a number of chromosomal abnormalities, the most frequent being trisomy 15, trisomy 8, isochromosome 17, translocations t(2;5)(p23;q31) and translocations t(5;12)(q33;p13) [10-14].

At the molecular level CEL has been divided into two entities, which has important therapeutic implications.


Chronic Eosinophilic Leukemia


The FIP1L1-PDGFRA rearrangement is caused by a cryptic deletion of 800kb on chromosome 4q12 and contains the CHIC2 gene [15], the incidence of this entity as part of the HES is not known, those with fusion protein rearrangements are very rare, estimated to be <1/100,000 persons with HES. The original work of Cools et al., [16] reported 56% of patients were FIP1L1-PDGFRA positive, however in those series with more than 10 patients with HES, the incidence of CEL FIP1L1-PDGFRA ranges from 3% to 56% [9]. Although these studies have selection bias, the incidence of patients positive for FIP1L1-PDGFRA is probably between 10-20% of patients presenting with HES in developed countries.

Fusion of FIP1L1 to the PDGFRA protein yields a constitutive active tyrosine kinase which stimulates the proliferation and mediates survival of the eosinophils in CEL patients, through activation of several signaling pathways including phosphoinositol3-kinase, ERK 1/2 and STAT5 [17,18]. The exact mechanism, however, by which FIP1L1–PDGFRA preferentially affects eosinophils, remains unclear.

FIP1L1-PDGFRA is a clonal marker associated with the myeloproliferative variant of hypereosinophilia [17,19]. These patients often present with organomegaly, a hypercellular bone marrow with increased mast cells and/or myelofibrosis and increased serum tryptase levels.

The use of low dose imatinib (100-400mg/day) produces complete and rapid hematological remissions and normalization of peripheral blood and bone marrow eosinophilia, with a median time to response of four weeks [20]. Molecular remissions, with patients becoming RT-PCR negative for FIP1L1-PDGFRA occurring after a median of 3 months [20,21]. However, discontinuation of imatinib can rapidly lead to relapse [17,22], with molecular remission being achieved following its reintroduction. A single weekly dose of 100-200mg of imatinib may be sufficient to maintain remission [18].

Acquired resistance to imatinib is much less frequent in patients with CEL FIP1L1-PDGFRA than that observed in CML patients. It is associated with the T674I mutation within the ATP binding domain of PDGFRA and may be seen in patients developing a blast crisis. The T674I confers broad spectrum resistance to tyrosine kinase inhibitors nilotinib, sorafenib [23], and dasatinib [23], ponatinib a pan-FIP1L1-PDGFRA inhibitor has shown in vitro activity in cells expressing the T674I mutation [24].


CEL-NOS is operationally defined by; an absolute peripheral eosinophilia count of >1.5 x 109/l; there is no philadelphia chromosome or BCR-ABL fusion gene detectable, is not part of another myeloproliferative neoplasms (polycythemia vera, essential thrombocytosis; myelofibrosis or systemic mastocytosis) or a myelodysplasia/myeloproliferation syndrome (CMML or atypical CML); there is no t(5;12) or other rearrangement of PDGFRB; there is no FIP1L1-PDGFRA fusion gene or other rearrangement of PDGFRA; there is no rearrangement of FGFR1 and finally the blast cell count in the peripheral blood is less than 2% and in the bone marrowbone marrow is between 5% and 20% and there is no inv(16)(p13;q22) ort(16;16)(p13;q22) or other feature diagnostic of AML [6].

In cases of CEL where the RT-PCR for FIP1L1-PDGFRA is negative or unknown, the prognosis is poor, being unresponsive or short lived to imatinib [25], conventional therapy [26] and has a high rate of acute transformation [26]. However, it has been reported that approximately 40% of patients who response to imatinib are negative for the FIP1L1-PDGFRA fusion protein, although doses as high as 600mg/day may not be effective [27]. The complete response rate has been reported as 24% compared with 98% of cases which were FIP1L1-PDGFRA positive [16]. However, hematological responses are often partial and short lived [26].

However, high doses of imatinib may not be tolerated, with grade 3 or 4 leukopenia, neutropenia, lymphopenia, trombocitopenia and anemia being reported in between 3 and 8% [20]. Fluid retention may require the use of diuretics and nausea and diarrhea may be sufficient to withhold therapy in 4% of patients [28].

Nevertheless the prognosis of CEL-NOS is poor in a cohort of 10 patients; the median survival was 22.2 months, with acute transformation occurring in 5 of the 10 patients [26].


In patients with eosinophilia, the presence of the FIP1L1-PDGFRA mutation is an indication for low dose imatinib and implies an excellent prognosis, though long term therapy is required. Those complying with the diagnostic criteria of CEL but are FIP1L1-PDGFRA negative, may warrant a trial of higher dose imatinib.


Mrs. Ana Maria Palazuelos for her help in the writing of this manuscript.


  1. Brigden M, Graydon C (1997) Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med 121: 963-967.
  2. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, et al. (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J allergy Clin Immunol 130: 607-612.
  3. Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133: 468-492.
  4. Crane MM, Chang CM, Kobayashi MG, Weller PF (2010) Incidence of myeloproliferative hypereosinophilia syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 126: 179-181.
  5. Bain BJ, Gilliland DG, Horny H-P, Vardiman JW (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, et al. (eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. (4thedn), IARC Press, Lyon, France. Pg no: 68-73.
  6. Bain BJ, Gilliland DG, Horny H-P, Vardiman JW (2008) Chronic eosinophilic leukaemia, not otherwise specified. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, et al. (eds.). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. (4thedn), IARC Press, Lyon, France. Pg no: 51-53.
  7. Vardiman JW (2008) Chronic myeloproliferative disorders and myelodysplastic/myeloproliferative disease. In: Jaffe ES, Stein H, Vardiman JW (eds.). WHO Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tumours. (4thedn), IARC Press, Lyon, France. Pg: 17-31.
  8. Balatzenko G, Stoyanov N, Bekrieva E, Guenova M (2011) Chronic eosinophilic leukemia with FIP1L1-PDGFRA transcripts after occupational and therapeutic exposure to radiation. Hematol Rep 3: 17.
  9. Gotlib J (2015) World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 90: 1077-1089
  10. Oliver JW, Deol I, Morgan DL, Tonk VS (1998) Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet 107: 111-117.
  11. Ma SK, Kwong YL, Shek TW, Wan TS, Chow EY, et al. (1999) The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Hum Pathol 30: 864-868.
  12. Saitoh T, Saiki M, Inoue M, Ishizuka H, Kura Y, et al. (2002) [CD25 positive chronic eosinophilic leukemia with myelofibrosis]. Rinsho Ketsueki 43: 918-923.
  13. Lepretre S, Jardin F, Buchonnet G, Lenain P, Stamatoullas A, et al. (2002) Eosinophilic leukemia associated with t(2;5)(p23;q31). Cancer Genet Cytogenet 133: 164-167.
  14. Granjo E, Lima M, Lopes JM, Dória S, Orfão A, et al. (2002) Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach: A case report. Acta Haematol 107: 108-112.
  15. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, et al. (2003) CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102: 3093-3096.
  16. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
  17. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, et al. (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104: 3038-3045.
  18. Helbig G, Stella-Ho?owiecka B, Majewski M, Ca?becka M, Gajkowska J, et al. (2008) A single weekly doe of imatinib is sufficient to induce and maintain remission in CEL FIP1L1-PDGFRA expressing patients. Br J Haematol 141: 200-204.
  19. Metzgeroth G, Erben P, Martin HS S Mousset, M Teichmann, et al. (2012) Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 26: 162-164.
  20. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, et al. (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92: 1173-1179.
  21. Klion AD, Robyn J, Akin C, Noel P, Brown M, et al. (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103: 473-478.
  22. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, et al. (2007) Low-dose imatinibmesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109: 4635-4640.
  23. Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, et al. (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108: 2332-2338.
  24. Jin Y, Ding K, Li H, Xue M, Shi X, et al. (2014) Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin. Mol Cancer 13: 17.
  25. Jain N, Cortes JK, Qunitas-Cardama A, Manshouri T, Luthra R, et al. (2009) Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status. Leuk Res 33: 837-839.
  26. Helbig G, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemie? S (2012) Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol 87: 643-645.
  27. Müller AM, Martens UM, Hofmann SC, Bruckner-Tuderman L, Mertelsmann R, et al. (2006) Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 85: 1-16.
  28. Datasheet Imatinib (Glievec) Novartis.

Citation: Murray NP (2015) Chronic Eosinophilic Leukemia: A Mini-Review. J Hematol Blood Transfus Disord 2: 004.

Copyright: © 2015  Nigel P Murray, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Herald Scholarly Open Access is a leading, internationally publishing house in the fields of Sciences. Our mission is to provide an access to knowledge globally.

© 2023, Copyrights Herald Scholarly Open Access. All Rights Reserved!